Strides Pharma Science · NSE: STAR · BSE: 532531

Q2 FY24 results · Jul–Sep 2023

Strides Pharma Science reported revenue from operations of ₹999.43 crore (up 11.4% from Q2 FY23) and net loss of ₹149.46 crore for Q2 FY24 (Jul–Sep 2023), on a consolidated basis.

Consolidated · ₹ crore
Item	Q2 FY24	Q2 FY23	YoY	Q1 FY24	QoQ
Revenue from operations	999.43	897.10	+11.4%	929.99	+7.5%
Other income	35.85	23.46	+52.8%	8.64	+314.7%
Total income	1,035.28	920.56	+12.5%	938.64	+10.3%
Profit before share of associates & JVs and tax	(114.64)	6.77	Turned loss	33.25	Turned loss
Share of profit/(loss) of associates & JVs	(42.25)	(44.84)		(32.93)
Net profit for the period	(149.46)	18.90	Turned loss	(9.36)	Loss widened
Attributable to shareholders of the company	(131.34)	22.82	Turned loss	(7.11)	Loss widened
EPS, basic (₹)	(14.54)	2.54	Turned loss	(0.79)	Loss widened
Net margin (%)	-15.0	2.1		-1.0

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q2 FY24	Q2 FY23	YoY	Q1 FY24	QoQ
Revenue from operations	540.29	481.24	+12.3%	475.32	+13.7%
Other income	22.34	20.47	+9.1%	11.65	+91.8%
Total income	562.63	501.71	+12.1%	486.97	+15.5%
Profit before tax	4.19	(44.07)	Turned profit	9.13	−54.1%
Net profit for the period	1.28	(4.00)	Turned profit	8.00	−84.0%
EPS, basic (₹)	0.14	(0.44)	Turned profit	0.89	−84.3%
Net margin (%)	0.2	-0.8		1.7

Consolidated

Filed with BSE: 01 Nov 2023, 09:12 IST
Board meeting: 30 Oct 2023
Period: 01 Jul 2023 to 30 Sep 2023
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 01 Nov 2023, 09:12 IST
Board meeting: 30 Oct 2023
Period: 01 Jul 2023 to 30 Sep 2023
Review status: Unaudited
Source: XBRL filing on BSE